Подписывайтесь на нас

Одна из главных задач Life4me+ — предотвращение новых случаев заражения ВИЧ-инфекцией и другими ИППП, гепатитом C и туберкулезом.

Приложение позволяет установить анонимную связь между врачами и ВИЧ-позитивными людьми, дает возможность организовать своевременный прием ваших медикаментов, получать замаскированные напоминания о них.

Назад
13 ноября 2013, 00:00
120

Новая комплексная терапия гепатита C показала неплохие результаты

Новая комплексная терапия гепатита C показала неплохие результаты - изображение 1

Abbott Park, Illinois (NYSE: ABT) — Results from Abbott’s phase 2b clinical trial, "Aviator," demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR12) in all 8- and 12-week arms, with combinations of direct acting antivirals (DAAs) given with and without ribavirin (RBV). Results will be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

Based on promising results from Aviator, Abbott has selected triple-DAA regimens, with and without ribavirin, to move forward into phase 3 clinical trials. Topline intent-to-treat results for the 12-week, triple-DAA regimen with ribavirin are as follows:

SVR12 in treatment-naïve genotype 1 (GT1) patients was 97.5 percent (77 of 79), and 93.3 percent (42 of 45) in GT1 null responder patients

In GT1a patients, SVR12 was achieved in 96 percent (52 of 54) of treatment naïve patients and 89 percent (25 of 28) of null responder patients

In GT1b patients, SVR12 was achieved in 100 percent of treatment naïve (25 of 25) and null responder patients (17 of 17)

In addition, results from the 12-week triple-DAA regimen without RBV in treatment naïve patients showed:

SVR12 was achieved in 87.3 percent (69 of 79) of GT1 patients

SVR12 in GT1a patients was 83 percent (43 of 52)

SVR12 in GT1b patients was 96 percent (24 of 25)

"Based on the high SVR12 results with Abbott’s triple-direct acting antiviral regimen in GT1 patients, it appears we are moving closer to potential oral treatment regimens that do not require interferon to treat HCV," said Kris Kowdley, M.D., director of the Liver Center of Excellence in the Digestive Disease Institute at Virginia Mason Medical Center, and Clinical Professor of Medicine at the University of Washington in Seattle. "This is encouraging news for the many patients who are unable or unwilling to take interferon."

Поделиться в соцсетях